1.

Record Nr.

UNISA990002867930203316

Titolo

Contributi alla cronologia albanese : [Vol.] 1.: età romano-bizantina dalla morte di Costantino alla morte di Teodosio e alla definitiva divisione dell'impero 337-395 d. C. / a cura di Giuseppe Valentini

Pubbl/distr/stampa

Roma : Reale Accademia D'italia, 1942

Descrizione fisica

8. p. 356 con una carta geografica e due tavole ; 24 cm

Collana

Fonti per la storia d'Albania ; 1

Disciplina

949.6503

Soggetti

Storia - Albania

Collocazione

949.6503 CON

Lingua di pubblicazione

Italiano

Formato

Materiale a stampa

Livello bibliografico

Monografia

2.

Record Nr.

UNISA996385877003316

Autore

Boyle Robert <1627-1691.>

Titolo

A defence of the doctrine touching the spring and weight of the air [[electronic resource] /] / propos'd by Mr. R. Boyle in his new physico-mechanical experiments, against the objections of Franciscus Linus ; wherewith the objector's funicular hypothesis is also examin'd, by the author of those experiments

Pubbl/distr/stampa

London, : Printed by F.G. for Thomas Robinson ..., 1662

Descrizione fisica

[12], 122 p., [1] leaf of plates : ill

Altri autori (Persone)

SharrockRobert <1630-1684.>

Soggetti

Air

Air-pump

Physics - Experiments

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

This work contains the first formulation of Boyle's law.



Edited by Robert Sharrock.

Errata: p. 122.

Reproduction of original in British Library.

Sommario/riassunto

eebo-0018

3.

Record Nr.

UNIORUON00393774

Autore

MARINESCU, Constanta

Titolo

George Cosbuc : Studiu critic / Constanta Marinescu

Pubbl/distr/stampa

Bucuresti, : Editura Literara a Casei Scoalelor, 1923

Descrizione fisica

336 p. ; 20 cm.

Disciplina

859

Soggetti

COSBUC GEORGE

Lingua di pubblicazione

Rumeno

Formato

Materiale a stampa

Livello bibliografico

Monografia



4.

Record Nr.

UNINA9910557489703321

Autore

Uchino Junji

Titolo

Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

Pubbl/distr/stampa

Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021

Descrizione fisica

1 online resource (258 p.)

Soggetti

Medicine

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Sommario/riassunto

Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to



cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.